References
- Full prescribing information for precedex. US Food and Drug Administration. [Internet]. [cited 1 Aug 2012] Available from http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021038s021lbl.pdf
- Mirski MA, Lewin JJ. Sedation and pain management in acute neurological disease. Seminars in Neurology 2008;28:611–630.
- Pandharipande PP, Pun BT, Herr DL, Maze M, Girard TD, Miller RR, Shintani AK, Thompson JL, Jackson JC, Deppen SA, et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: The MENDS randomized controlled trial. Journal of the American Medical Association 2007;298:2644–2653.
- Riker RR, Shehabi Y, Bokesch PM, Ceraso D, Wisemandle W, Koura F, Whitten P, Margolis BD, Byrne DW, Ely EW, et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. Journal of the American Medical Association 2009;301:489–499.
- Jakob SM, Ruokonen E, Grounds RM, Sarapohja T, Garratt C, Pocock SJ, Bratty JR, Takala J; Dexmedetomidine for Long-Term Sedation Investigators. Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials. Journal of the American Medical Association 2012;307:1151–1160.
- Martin E, Ramsay G, Mantz J, Sum-Ping STJ. The role of the α2-adrenoceptor agonist dexmedetomidine in postsurgical sedation in the intensive care unit. Journal of Intensive Care Medicine 2003;18:29–41.
- Triltsch AE, Welte M, von Homeyer P, Grosse J, Genähr A, Moshirzadeh M, Sidiropoulos A, Konertz W, Kox WJ, Spies CD. Bispectral index-guided sedation with dexmedetomidine in intensive care: a prospective, randomized, double blind, placebo-controlled phase II study. Critical Care Medicine 2002;30:1007–1014.
- Venn RM, Hell J, Michael Grounds R. Respiratory effects of dexmedetomidine in the surgical patient requiring intensive care. Critical Care 2000;4:302.
- Aryan HE MD, Box KW, Ibrahim D, Desiraju U, Ames CP. Safety and efficacy of dexmedetomidine in neurosurgical patients. Brain Injury 2006;20:791–798.
- Grof TM, Grof TM, Bledsoe KA, Bledsoe KA. Evaluating the use of dexmedetomidine in neurocritical care patients. Neurocritical Care 2010;12:356–361.
- James ML, Olson DM, Graffagnino C. A pilot study of cerebral and haemodynamic physiological changes during sedation with dexmedetomidine or propofol in patients with acute brain injury. Anaesthesia and Intensive Care. 2012;40:949–957.
- Tarabrin O, Shcherbakov S, Gavrychenko D, Mazurenko G. Comparison of dexmedetomidine and propofol for sedation in patients with traumatic brain injury. Critical Care 2014;18(Suppl 1):P416.
- Wang X, Ji J, Fen L, Wang A. Effects of dexmedetomidine on cerebral blood flow in critically ill patients with or without traumatic brain injury: a prospective controlled trial. Brain Injury 2013;27:1617–1622.
- Tang JF, Chen PL, Tang EJ, May TA, Stiver SI. Dexmedetomidine controls agitation and facilitates reliable, serial neurological examinations in a non-intubated patient with traumatic brain injury. Neurocritical Care 2011;15:175–181.
- Flower O, Hellings S. Sedation in traumatic brain injury. Emergency Medicine International 2012;2012:637171.
- Goddeau RP Jr., Silverman SB, Sims JR. Dexmedetomidine for the treatment of paroxysmal autonomic instability with dystonia. Neurocritical Care 2007;7:217–220.
- Maier C, Steinberg GK, Sun GH, Zhi GT, Maze M. Neuroprotection by the alpha 2-adrenoreceptor agonist dexmedetomidine in a focal model of cerebral ischemia. Anesthesiology 1993;79:306–312.
- Kuhmonen J, Haapalinna A, Sivenius J. Effects of dexmedetomidine after transient and permanent occlusion of the middle cerebral artery in the rat. Journal of Neural Transmission 2001;108:261–271.
- Nakano T, Okamoto H. Dexmedetomidine-induced cerebral hypoperfusion exacerbates ischemic brain injury in rats. Journal of Anesthesia 2009;23:378–384.